320.06
-0.28 (-0.09%)
| 前收盘价格 | 320.34 |
| 收盘价格 | 320.00 |
| 成交量 | 88,019 |
| 平均成交量 (3个月) | 217,532 |
| 市值 | 8,633,566,208 |
| 预期市盈率 (P/E Forward) | 34.01 |
| 价格/销量 (P/S) | 3.50 |
| 股市价格/股市净资产 (P/B) | 1.30 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | -85.16% |
| 营业利益率 (TTM) | 9.72% |
| 稀释每股收益 (EPS TTM) | -76.53 |
| 季度收入增长率 (YOY) | -4.20% |
| 季度盈利增长率 (YOY) | -83.30% |
| 总债务/股东权益 (D/E MRQ) | 20.50% |
| 流动比率 (MRQ) | 5.99 |
| 营业现金流 (OCF TTM) | 515.30 M |
| 杠杆自由现金流 (LFCF TTM) | 250.23 M |
| 资产报酬率 (ROA TTM) | 1.55% |
| 股东权益报酬率 (ROE TTM) | -27.52% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Bio-Rad Laboratories, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.75 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 16.14% |
| 机构持股比例 | 93.04% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Veritas Asset Management Llp | 30 Sep 2025 | 844,039 |
| Parnassus Investments, Llc | 30 Sep 2025 | 315,328 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 375.00 (Citigroup, 17.17%) | 购买 |
| 中 | 357.50 (11.70%) | |
| 低 | 340.00 (Wells Fargo, 6.23%) | 保留 |
| 平均值 | 357.50 (11.70%) | |
| 总计 | 1 购买, 1 保留 | |
| 平均价格@调整类型 | 304.61 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 30 Oct 2025 | 375.00 (17.17%) | 购买 | 304.61 |
| Wells Fargo | 30 Oct 2025 | 340.00 (6.23%) | 保留 | 304.61 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 29 Oct 2025 | 公告 | Bio-Rad Reports Third-Quarter 2025 Financial Results |
| 16 Oct 2025 | 公告 | Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025 |
| 29 Sep 2025 | 公告 | Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合